FDA approvals: Lumvoa leads 9 actions
This week’s FDA approvals digest covers nine actions from June 19–26, led by Lumvoa and spanning drug expansions, a delivery-device approval, and three 510(k) clearances.
Lumvoa made this a launch week, not just an approvals week. From June 19 at 5:23 p.m. through June 26 at 5:00 p.m. ET, the FDA cleared or approved nine qualifying drug, device, and drug-device actions: one new molecular entity, four therapeutic label expansions, one pre-filled pen presentation, and three device 510(k) clearances.
This week at a glance
| Date | Product | Sponsor | Action type | What changed |
|---|---|---|---|---|
| June 26 | Lumvoa (veligrotug-vvze) | Viridian Therapeutics | New molecular entity / BLA | First TED drug label covering both active and chronic disease, with 5 IV infusions over 12 weeks. 12 |
| June 24 | Tryngolza (olezarsen) | Ionis Pharmaceuticals | Label expansion | Expanded from familial chylomicronemia syndrome to adults with severe hypertriglyceridemia to lower triglycerides and acute pancreatitis risk. 34 |
| June 24 | Trodelvy (sacituzumab govitecan-hziy) | Gilead Sciences | Label expansion | Moved into first-line unresectable locally advanced or metastatic TNBC as monotherapy for patients ineligible for PD-1/PD-L1 inhibitors and with pembrolizumab for PD-L1-positive disease. 56 |
| June 22 | Tecelra (afamitresgene autoleucel) | US WorldMeds | Full approval and label expansion | Converted from accelerated to full approval and expanded to patients aged 12 and older with biomarker-eligible advanced synovial sarcoma. 7 |
| June 24 | Ibrance (palbociclib) | Pfizer | Label expansion | Added maintenance use with trastuzumab, with or without pertuzumab, and endocrine therapy after induction therapy in HR-positive, HER2-positive advanced or metastatic breast cancer. 89 |
| June 26 | BESREMi Pen (ropeginterferon alfa-2b-njft) | PharmaEssentia USA | Drug-device delivery approval | Added a pre-filled pen for adult polycythemia vera self-administration; commercial availability is expected in the coming weeks. 10 |
| June 22 | Radius VSM OIRD detection | Masimo | 510(k) clearance | Added AI-enabled opioid-induced respiratory depression detection to a wearable continuous patient monitor. 11 |
| June 22 | FindAir ONE for pMDI 1.2 | FindAir | 510(k) clearance | Cleared a smart add-on that turns pressurized metered-dose inhalers into connected medication-use devices. 12 |
| June 23 | Dynamis Robotic Surgical System | LEM Surgical | 510(k) clearance | Added spine-surgery capabilities, including bilateral workflow and independent multi-vertebra tracking. 13 |
New drug approval
Lumvoa — the first real TED launch challenge to Tepezza
What changed: Lumvoa (veligrotug-vvze), a humanized monoclonal antibody that fully antagonizes insulin-like growth factor-1 receptor, became FDA novel drug approval #23 of 2026 and is approved for thyroid eye disease regardless of disease activity or duration. 12 The label matters because Tepezza, the prior TED incumbent, has been centered on active disease; Lumvoa enters with data in both active and chronic TED and a shorter regimen of 500 mg IV every three weeks for five infusions over 12 weeks. 214
Evidence and safety: The approval rests on THRIVE in active TED and THRIVE-2 in chronic TED; both global Phase 3 trials met their primary endpoints and all secondary endpoints at Week 15. 2 Viridian reported proptosis reduction as early as Week 3 and statistically significant diplopia response and complete resolution in both active and chronic disease. 2 The clinical caution is the class safety profile: the label warns about infusion reactions, inflammatory bowel disease, hyperglycemia, and hearing impairment, including severe hearing impairment and permanent hearing loss. 14
Commercial read: Viridian Therapeutics is a first-time commercial company based in Waltham, Massachusetts, and the company plans immediate launch with prescribing beginning June 27 and a ViridianCares patient support program. 2 The investor question is not whether TED is a validated market: Tepezza generated about $1.9 billion in 2025 sales. 15 The question is whether physicians and payers will value chronic-disease label breadth and 5-infusion convenience enough to shift patients from the incumbent. Pricing was not public in the approval materials, so reimbursement and gross-to-net assumptions should wait for Viridian's first launch commentary. 2
Follow-up anchor: Watch Viridian's June 29 investor call for price, payer access language, and early field-force commentary; those details will matter more than the approval itself for near-term VRDN valuation.
Drug label expansions
Tryngolza — a common-disease expansion for Ionis
What changed: Tryngolza (olezarsen), an antisense oligonucleotide that targets hepatic APOC3 mRNA, expanded from familial chylomicronemia syndrome to adults with severe hypertriglyceridemia, defined as triglycerides of at least 500 mg/dL. 34 The dosing format is monthly subcutaneous self-injection by autoinjector at 50 mg or 80 mg. 3
Evidence and safety: FDA cited the Phase 3 CORE and CORE2 trials, which enrolled 617 and 446 patients, respectively; Ionis reported fasting triglyceride reductions of 49% to 72% at six months, an 85% reduction in pooled acute pancreatitis events at 12 months, and 86% of treated patients reaching triglycerides below 500 mg/dL. 34 Common adverse reactions included injection-site reactions and liver enzyme elevation, and the 80 mg dose had more liver enzyme elevations and thrombocytopenia. 3
Commercial read: Ionis describes more than 3 million US adults as having severe hypertriglyceridemia and about 1 million as higher-risk patients, making this the company's first independent commercial launch in a common disease. 3 The practical clinical test is whether lipid clinics and primary-care systems identify pancreatitis-risk patients who fit the label, rather than treating this as another triglyceride-lowering option for broad dyslipidemia.
Follow-up anchor: Track July launch execution, payer criteria around prior pancreatitis or triglyceride thresholds, and real-world use of the 50 mg versus 80 mg dose.
Trodelvy — first-line TNBC becomes a broader ADC contest
What changed: Trodelvy, Gilead's Trop-2-directed antibody-drug conjugate carrying the SN-38 topoisomerase I inhibitor payload, now has two first-line triple-negative breast cancer indications. 5 The monotherapy label covers adults with unresectable locally advanced or metastatic TNBC who are ineligible for PD-1 or PD-L1 inhibitors, while the combination label covers PD-L1-positive tumors with a combined positive score of at least 10 when used with Keytruda or Keytruda Qlex. 6
Evidence and safety: In ASCENT-03, Trodelvy monotherapy improved median progression-free survival to 9.7 months versus 6.9 months with chemotherapy, with a hazard ratio of 0.62. 6 In ASCENT-04/KEYNOTE-D19, Trodelvy plus Keytruda improved median progression-free survival to 11.2 months versus 7.8 months for Keytruda plus chemotherapy, with a hazard ratio of 0.65. 6 Trodelvy still carries boxed warnings for severe neutropenia and severe diarrhea. 5
Commercial read: The approval puts Trodelvy across nearly the full first-line metastatic TNBC decision tree and gives Gilead a direct answer to Datroway, the AstraZeneca/Daiichi Sankyo Trop-2 ADC that gained a first-line TNBC monotherapy approval in May 2026. 16 The competitive split is now cleaner: PD-L1-positive patients can be considered for the Trodelvy-Keytruda combination, while immunotherapy-ineligible patients become the ADC monotherapy battleground.
Follow-up anchor: Monitor NCCN uptake, community-oncology sequencing choices, and whether Datroway or Trodelvy earns clearer physician preference in PD-L1-negative and immunotherapy-ineligible patients.
Tecelra — full approval and adolescent access for a solid-tumor T-cell therapy
What changed: Tecelra (afamitresgene autoleucel), an autologous engineered T-cell therapy, converted from accelerated approval to full approval and expanded from adults to patients aged 12 and older. 7 The indication remains narrow: unresectable or metastatic synovial sarcoma after chemotherapy in patients with eligible HLA-A*02 subtypes and MAGE-A4 tumor expression confirmed by an FDA-approved or cleared companion diagnostic. 7
Evidence and safety: SPEARHEAD-1 cohorts 1 through 3 enrolled 137 patients aged 10 to 75; Tecelra produced an overall response rate of 43.8%, a complete response rate of 3.6%, median duration of response of 5.3 months, and response duration of at least 24 months in 31.9% of responders. 7 The treatment has a boxed warning for cytokine release syndrome, and patients must remain near a treatment facility for at least two weeks after infusion. 7
Commercial read: The label extension is important for pediatric and young-adult sarcoma centers because about one-third of synovial sarcoma patients are diagnosed before age 30, and metastatic disease has about a 20% five-year survival rate. 7 The commercial ceiling remains constrained by HLA and MAGE-A4 testing, manufacturing logistics, and treatment-center capacity.
Follow-up anchor: Patient advocates should watch whether additional pediatric sarcoma centers become activated sites and whether companion diagnostic access keeps pace with the expanded age range.
Ibrance — Pfizer extends CDK4/6 use into HR+/HER2+ maintenance
What changed: Ibrance (palbociclib), Pfizer's oral CDK4/6 inhibitor, is now approved with trastuzumab, with or without pertuzumab, plus endocrine therapy as maintenance treatment after induction therapy for adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer. 89 Pfizer says this makes Ibrance the first CDK4/6 inhibitor indicated for HR-positive metastatic breast cancer regardless of HER2 status. 8
Evidence and safety: PATINA, a randomized open-label Phase 3 trial with 518 patients, tested Ibrance plus anti-HER2 and endocrine maintenance against anti-HER2 and endocrine maintenance after induction therapy. 9 FDA reported a progression-free survival hazard ratio of 0.76, with a one-sided p value of 0.0134; overall survival data were immature. 9 In PATINA, neutropenia occurred in 78% of patients and grade 3 or higher neutropenia occurred in 61%; febrile neutropenia was reported in 0.8%. 8
Commercial read: HR-positive, HER2-positive breast cancer represents about 10% of all breast cancer, so this is an incremental lifecycle-management win rather than a market reset. 8 The adoption debate will center on whether a 24% reduction in progression or death risk justifies added cytopenia monitoring in patients already receiving anti-HER2 and endocrine therapy.
Follow-up anchor: Watch mature overall survival data from PATINA and payer language around maintenance duration after induction response.
Devices and delivery systems
BESREMi Pen — convenience for a chronic myeloproliferative disease
What changed: FDA approved BESREMi Pen, a pre-filled pen presentation of ropeginterferon alfa-2b-njft for adults with polycythemia vera. 10 The product was previously available as a pre-filled syringe, so the change is administration convenience rather than a new drug indication. 10
Clinical and commercial read: Polycythemia vera is a chronic blood cancer that often requires long-term therapy, and PharmaEssentia positions the pen as a way to simplify self-administration and support adherence. 10 BESREMi is approved in more than 40 countries, and PharmaEssentia has submitted a supplemental BLA for essential thrombocythemia. 10 The exact FDA pathway for the pen presentation was not specified in the release; the research package did not independently confirm a 510(k) or PMA database entry, so the clean description is FDA approval of a new delivery presentation.
Follow-up anchor: Track when the pen becomes commercially available and whether hematology practices switch existing syringe patients at refill rather than waiting for new starts.
Masimo Radius VSM — OIRD monitoring moves into wearable surveillance
What changed: Masimo received 510(k) clearance for AI-enabled opioid-induced respiratory depression detection on Radius VSM, a wearable continuous patient monitor powered by the smartSET pulse oximetry platform. 11 The feature analyzes continuous physiological data and escalates visual alarms as OIRD risk increases. 11
Clinical and commercial read: This is a workflow product for hospitals using opioids post-operatively or in monitored wards, not a consumer wearable. Masimo says this is the first implementation of its OIRD detection technology in a hospital monitoring solution, and the company frames smartSET as a platform for additional pattern-recognition algorithms. 11 For hospital buyers, the relevant question is alarm burden and integration into central monitoring, not just detection accuracy.
Follow-up anchor: Look for early implementation data on false alarms, nursing response protocols, and whether Danaher uses Masimo's hospital footprint to bundle smartSET-enabled monitoring upgrades.
FindAir ONE for pMDI 1.2 — a respiratory-data layer for RPM programs
What changed: FindAir ONE for pMDI 1.2 received 510(k) clearance as an add-on for pressurized metered-dose inhalers, turning traditional inhalers into connected medication-use devices. 12 FindAir says the add-on is compatible with more than 90% of globally used inhaler formats and can feed objective medication data into remote patient monitoring and remote therapeutic monitoring platforms through APIs and SDKs. 12
Clinical and commercial read: The product does not ask prescribers to change asthma or COPD medications; it changes the data layer around adherence, dose timing, inhalation technique, and medication release. 12 That makes the US opportunity more partner-led than direct-to-patient. FindAir reports more than 14,000 delivered smart medical devices, nearly 80 institutional clients, and deployment in more than 50 hospitals in Europe. 12
Follow-up anchor: Watch for US RPM platform partnerships, because reimbursement-linked integration will determine whether the clearance becomes revenue or remains a technical milestone.
LEM Dynamis — spine robotics adds a multi-arm architecture
What changed: LEM Surgical received its second FDA 510(k) clearance for the Dynamis Robotic Surgical System, adding spine-surgery capabilities after a first clearance in April 2025. 13 Newly cleared capabilities include simultaneous bilateral workflow, continuous independent tracking of multiple vertebrae, and intraoperative quantification of spinal realignment. 13
Clinical and commercial read: Dynamis differs from the single-arm robot-plus-stationary-camera model by using an upper-torso humanoid configuration with multiple robotic arms, including one arm that stabilizes or controls a vertebral segment while another performs the clinical intervention. 13 The clearance gives LEM a sharper product story in spine robotics, but the research package did not contain executive quotes, pricing, installed-base data, or hospital purchase commitments.
Follow-up anchor: Track first US clinical installations, surgeon training claims, and whether the system shows measurable procedure-time, alignment, or revision-rate advantages over incumbent robotic spine platforms.
Actionable signals
For investors: Lumvoa is the only brand-new commercial launch this week, and VRDN's next data point is launch execution rather than approval risk. 2 Tryngolza is Ionis's first common-disease solo launch, so payer criteria may matter more than the headline population size. 3 Trodelvy and Ibrance are lifecycle-expansion stories; the signal is guideline adoption and sequencing, not immediate market creation. 58 Masimo, FindAir, and LEM all need implementation evidence before their clearances support durable revenue assumptions. 111213
For clinicians: Lumvoa adds an active-and-chronic TED option but requires hearing, glucose, infusion-reaction, and IBD monitoring. 14 Trodelvy changes first-line TNBC treatment selection around PD-L1 status and immunotherapy eligibility. 6 Tecelra expansion requires biomarker testing and cell-therapy referral pathways for adolescents. 7 Ibrance maintenance adds neutropenia monitoring to HR-positive, HER2-positive maintenance care. 8
For patient advocates: The access work this week is practical: TED patients need payer coverage and hearing-risk counseling for Lumvoa; severe hypertriglyceridemia patients need identification before pancreatitis recurrence; synovial sarcoma families need biomarker testing and referral-center navigation; respiratory patients may benefit from connected-inhaler data only if RPM programs actually absorb the device. 23712
Cover image: Lumvoa vial image from StockTitan / BusinessWire.
References
- 1
- 2Viridian / BusinessWire: Lumvoa FDA approval and launch
stocktitan.net
- 3
- 4
- 5
- 6
- 7US WorldMeds: Tecelra full FDA approval
prnewswire.com
- 8
- 9
- 10PharmaEssentia / BusinessWire: BESREMi Pen FDA approval
businesswire.com
- 11Masimo: Radius VSM OIRD 510(k) clearance
masimo.com
- 12
- 13GGBa: LEM Surgical second FDA clearance
ggba.swiss
- 14Viridian: Lumvoa prescribing information
viridiantherapeutics.com
- 15MerlinTrader: Viridian PDUFA context
merlintrader.com
- 16
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.